Direkt zum Inhalt
Merck

Hypomorphic pathogenic variant in SFTPB leads to adult pulmonary fibrosis.

European journal of human genetics : EJHG (2023-06-29)
Tifenn Desroziers, Grégoire Prévot, Aurore Coulomb, Valérie Nau, Florence Dastot-Le Moal, Philippe Duquesnoy, Mélanie Héry, Aurélie Le Borgne, Serge Amselem, Marie Legendre, Nadia Nathan
ZUSAMMENFASSUNG

Biallelic pathogenic variants in the surfactant protein (SP)-B gene (SFTPB) have been associated with fatal forms of interstitial lung diseases (ILD) in newborns and exceptional survival in young children. We herein report the cases of two related adults with pulmonary fibrosis due to a new homozygous SFTPB pathogenic variant, c.582G>A p.(Gln194=). In vitro transcript studies showed that this SFTPB synonymous pathogenic variant induces aberrant splicing leading to three abnormal transcripts with the preservation of the expression of a small proportion of normal SFTPB transcripts. Immunostainings on lung biopsies of the proband showed an almost complete loss of SP-B expression. This hypomorphic splice variant has thus probably allowed the patients' survival to adulthood while inducing an epithelial cell dysfunction leading to ILD. Altogether, this report shows that SFTPB pathogenic variants should be considered in atypical presentations and/or early-onset forms of ILD particularly when a family history is identified.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Anti-SFTPB antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution